AxoGen rivals ‘not a real threat’: Jefferies

AxoGen competition just noise, not a real threat, says Jefferies. After hosting management at his firm’s conference, Jefferies analyst Raj Denhoy says “all seems to be going the right direction” for AxoGen (AXGN). Not only is surgeon acceptance of the company’s nerve repair products growing but there is more product being used per procedure, Denhoy tells investors in a research note. Further, he believes questions on competition are just noise and not a real threat. The analyst remains skeptical that Integra LifeSciences (IART) “can do much to slow” AxoGen’s momentum. Denhoy keeps a Buy rating on AxoGen with a $45 price target.

https://bit.ly/2xW5y8X